Pregabalin in the Prevention of Postoperative Delirium and Pain
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether administration of pregabalin by mouth immediately preoperatively and three times daily for 3 days after surgery reduces the incidence of delirium postoperatively and improves overall pain control.
| Condition | Intervention | Phase |
|---|---|---|
|
Delirium Pain |
Drug: Pregabalin Other: Sugar pill |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of the Perioperative Administration of Pregabalin in Reducing the Incidence of Postoperative Delirium and Improving Acute Postoperative Pain Management |
- Delirium (patient is either CAM-ICU positive or positive for delirium by chart review) [ Time Frame: postoperative day 1, 2, 3 ] [ Designated as safety issue: No ]
- Interference with daily activities using BPI [ Time Frame: postoperative day 3 ] [ Designated as safety issue: No ]
- Pain at rest using NRS [ Time Frame: postoperative days 1, 2, 3 ] [ Designated as safety issue: No ]
- Pain with movement of the operative site using NRS [ Time Frame: postoperative days 1, 2, 3 ] [ Designated as safety issue: No ]
- Narcotic analgesic requirements [ Time Frame: postoperative days 0, 1, 2, 3 ] [ Designated as safety issue: No ]
- Sedation using RSS [ Time Frame: postoperative days 1, 2, 3 ] [ Designated as safety issue: Yes ]
- Narcotic-related adverse effects using ORSDS [ Time Frame: postoperative days 1, 2, 3 ] [ Designated as safety issue: Yes ]
- Recovery using the QoR [ Time Frame: postoperative day 3 ] [ Designated as safety issue: No ]
- Length of stay [ Time Frame: Discharge day ] [ Designated as safety issue: Yes ]
- Medical Outcome Study (MOS) sleep score [ Time Frame: Postoperative day 3 ] [ Designated as safety issue: No ]
| Enrollment: | 240 |
| Study Start Date: | May 2009 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Sugar pill
Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
|
Other: Sugar pill
Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
|
|
Experimental: Pregabalin
Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
|
Drug: Pregabalin
Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
Other Name: Lyrica
|
Detailed Description:
Delirium is a common postoperative complication occurring in up to 73% of patients sometime during their hospital stay. Elderly patients undergoing major surgical procedures are at highest risk. While many risk factors for delirium are known, the specific pathophysiology of postoperative delirium remains unclear and is likely multifactorial. The most common inciting agents and events include metabolic causes, medications, blood loss, hypoxemia and pain. Pain and its management are intimately related to the likelihood of developing postoperative delirium. As a class, gabapentinoids, such as pregabalin, have proven to reduce postoperative pain and narcotic consumption and therefore may have a role to play in the prevention of postoperative delirium.
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- aged 60 years and older
- booked for major orthopaedic or vascular procedure
- expected length of stay > 2 days
Exclusion Criteria:
- open AAA repair
- EVAR
- allergy/sensitivity to pregabalin or gabapentin
- use of pregabalin or gabapentin in previous 14 days
- severe liver disease
- severe renal dysfunction defined as either having creatinine clearance < 30 ml/min or being dialysis-dependent
- seizure disorder
- MMSE < 24/30
- inability to speak English or French
Contacts and Locations| Canada, Ontario | |
| The Ottawa Hospital | |
| Ottawa, Ontario, Canada, K1Y 4E9 | |
| Principal Investigator: | Alan J Chaput, MD, MSc | The Ottawa Hospital |
| Study Director: | Homer Yang, MD | The Ottawa Hospital |
| Study Director: | Gregory L Bryson, MD, MSc | The Ottawa Hospital |
| Study Director: | Holly Evans, MD | The Ottawa Hospital |
| Study Director: | Paul Beaule, MD | The Ottawa Hospital |
| Study Director: | Prasad Jetty, MD | The Ottawa Hospital |
| Study Director: | Barbara Power, MD | The Ottawa Hospital |
More Information
Publications:
| Responsible Party: | Dr. A. Chaput, Clinician Investigator, Ottawa Hospital Research Institute |
| ClinicalTrials.gov Identifier: | NCT00819988 History of Changes |
| Other Study ID Numbers: | PSI2008525 |
| Study First Received: | January 8, 2009 |
| Last Updated: | January 9, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Ottawa Hospital Research Institute:
|
Postoperative Perioperative Orthopedic surgery Vascular surgery Gabapentinoid |
Additional relevant MeSH terms:
|
Delirium Confusion Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Pregabalin |
Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anticonvulsants |
ClinicalTrials.gov processed this record on June 18, 2013